Ibogaine and Lemborexant

Moderate caution. Dual orexin receptor antagonist prescribed for insomnia. Additive CNS and respiratory depression with ibogaine's sedating phase. CYP3A4 substrate. Hold on the dosing day and through the acute phase unless the supervising physician directs otherwise; resume when the patient is settled. Not a pre-arrival washout.

Continue as prescribed — cleared by a measured lab value, not a waiting period. This medication is not stopped for treatment, and should not be stopped on our initiative — the condition it treats usually outranks the interaction. What it changes is monitoring: serum potassium and magnesium are measured before the flood dose and corrected to target, and the dose is deferred until those numbers are right rather than until a number of days have passed. Any change to the prescription belongs to the prescribing physician.

Central nervous system depression. Sedatives — benzodiazepines, gabapentinoids, alcohol, sedating antihistamines, sleep aids — add to ibogaine's own sedation, ataxia, and respiratory effects. Concomitant CNS depressants are tapered before treatment and reintroduced cautiously after the active dosing window closes.

In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Lemborexant — contact us for an individual review.